## Clinical Trials January 2018

<table>
<thead>
<tr>
<th>Protocol</th>
<th>Title</th>
<th>Study Site</th>
<th>PI Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-285</td>
<td>Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer</td>
<td>Oncology Network</td>
<td>Dr. Cheryl Jones</td>
</tr>
<tr>
<td></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02750826">https://www.clinicaltrials.gov/ct2/show/NCT02750826</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-301</td>
<td>A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer</td>
<td>Oncology Network</td>
<td>Dr. Amelia Zelnak</td>
</tr>
<tr>
<td></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03078751">https://www.clinicaltrials.gov/ct2/show/NCT03078751</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSH1126</td>
<td>A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy</td>
<td>Oncology Network</td>
<td>Dr. Amelia Zelnak</td>
</tr>
<tr>
<td></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02445391">https://www.clinicaltrials.gov/ct2/show/NCT02445391</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-239</td>
<td>A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Invasive TNBC</td>
<td>Oncology Network</td>
<td>Dr. Amelia Zelnak</td>
</tr>
<tr>
<td></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02488967">https://www.clinicaltrials.gov/ct2/show/NCT02488967</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-295</td>
<td>A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy</td>
<td>Oncology Network</td>
<td>Dr. Amelia Zelnak</td>
</tr>
<tr>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02954874">https://clinicaltrials.gov/ct2/show/NCT02954874</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-197</td>
<td>A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy</td>
<td>Oncology Network</td>
<td>Dr. Cheryl Jones</td>
</tr>
<tr>
<td></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02032823">https://www.clinicaltrials.gov/ct2/show/NCT02032823</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-294</td>
<td>A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial</td>
<td>Oncology Network</td>
<td>Dr. Gena Volas-Redd</td>
</tr>
<tr>
<td></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02927249">https://www.clinicaltrials.gov/ct2/show/NCT02927249</a></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For more information and/or to refer a patient, please email CLINICAL TRIALS@NORTHSIDE.COM

Page 1 of 6
## Clinical Trials January 2018

<table>
<thead>
<tr>
<th>Protocol</th>
<th>Title</th>
<th>Study Site</th>
<th>PI Name</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>C-266</strong>&lt;br&gt;ONT-380-206</td>
<td>Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma <a href="https://www.clinicaltrials.gov/ct2/show/NCT02614794">https://www.clinicaltrials.gov/ct2/show/NCT02614794</a></td>
<td>Oncology Network</td>
<td>Dr. Amelia Zelnak</td>
</tr>
<tr>
<td><strong>C-259</strong>&lt;br&gt;i3Y-MC-JPBZ monarchHER</td>
<td>A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician’s Choice plus Trastuzumab in Women with HR+, HER2+ Locally Advanced or Metastatic Breast Cancer <a href="https://www.clinicaltrials.gov/ct2/show/NCT02675231">https://www.clinicaltrials.gov/ct2/show/NCT02675231</a></td>
<td>Oncology Network</td>
<td>Dr. Amelia Zelnak</td>
</tr>
<tr>
<td><strong>C-276</strong>&lt;br&gt;CLEE011XUS29 TRINITI-1</td>
<td>A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor <a href="https://www.clinicaltrials.gov/ct2/show/NCT02732119">https://www.clinicaltrials.gov/ct2/show/NCT02732119</a></td>
<td>Oncology Network</td>
<td>Dr. Amelia Zelnak</td>
</tr>
<tr>
<td><strong>C-247</strong>&lt;br&gt;REPO114; FRIDA 1st line Metastatic TNBC Post Adjuvant Therapy</td>
<td>A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixtin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple-Negative Breast Cancer <a href="https://www.clinicaltrials.gov/ct2/show/NCT02370238">https://www.clinicaltrials.gov/ct2/show/NCT02370238</a></td>
<td>Oncology Network</td>
<td>Dr. Amelia Zelnak</td>
</tr>
<tr>
<td><strong>C-311</strong>&lt;br&gt;IMMU-132-05 2nd line Metastatic TNBC</td>
<td>An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments <a href="https://www.clinicaltrials.gov/ct2/show/NCT02574455">https://www.clinicaltrials.gov/ct2/show/NCT02574455</a></td>
<td>Oncology Network</td>
<td>Dr. Amelia Zelnak</td>
</tr>
<tr>
<td><strong>C-287</strong>&lt;br&gt;A5481074 MADELINE Advanced/ Metastatic breast cancer 1st/2nd/3rd Line</td>
<td>Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer</td>
<td>Oncology Network</td>
<td>Dr. Cheryl Jones</td>
</tr>
<tr>
<td>Protocol</td>
<td>Title</td>
<td>Study Site</td>
<td>PI Name</td>
</tr>
<tr>
<td>----------</td>
<td>-------</td>
<td>------------</td>
<td>---------</td>
</tr>
<tr>
<td>C-258</td>
<td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy</td>
<td>GYN Onc</td>
<td>Dr. Stephanie Yap</td>
</tr>
<tr>
<td>NSH1083</td>
<td>A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer</td>
<td>GYN Onc</td>
<td>Dr. Guilherme Cantuaria</td>
</tr>
<tr>
<td>NSH998</td>
<td>Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival?</td>
<td>GYN Onc &amp; Macon</td>
<td>Dr. Guilherme Cantuaria</td>
</tr>
<tr>
<td>NSH1025</td>
<td>A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemo naïve Sex Cord-Stromal Tumors of the Ovary</td>
<td>GYN Onc &amp; Macon</td>
<td>Dr. Guilherme Cantuaria</td>
</tr>
<tr>
<td>NSH1091</td>
<td>A Randomized Phase II/III Study of Paclitaxel/ Carboplatin/ Metformin Versus Paclitaxel/ Carboplatin/ Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer</td>
<td>GYN Onc</td>
<td>Dr. Guilherme Cantuaria</td>
</tr>
<tr>
<td>C-304</td>
<td>A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Endometrial Carcinoma</td>
<td>GYN Onc</td>
<td>Dr. Meaghan Tenney</td>
</tr>
<tr>
<td>NSH1145</td>
<td>Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome</td>
<td>Oncology Network</td>
<td>Dr. Sreekanth Reddy</td>
</tr>
<tr>
<td>C-093</td>
<td>A phase 2 open-label study of brentuximab vedotin infron-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above</td>
<td>Oncology Network</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>Protocol</td>
<td>Title</td>
<td>Study Site</td>
<td>PI Name</td>
</tr>
<tr>
<td>----------</td>
<td>-------</td>
<td>------------</td>
<td>---------</td>
</tr>
<tr>
<td>C-195</td>
<td>Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (Vrd) Vs Carfilzomib, Lenalidomide and Dexamethasone (CrD) Followed by Limited or Indefinite DURation Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma</td>
<td>Oncology Network</td>
<td>Dr. Kathleen Lambert</td>
</tr>
<tr>
<td>C-190</td>
<td>Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials</td>
<td>Oncology Network</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>C-191</td>
<td>Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC</td>
<td>Oncology Network</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>C-192</td>
<td>A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein</td>
<td>Oncology Network</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>C-280</td>
<td>Adjuvant Nivolumab in Resected Lung Cancers (ANVIL): A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in NSCLC</td>
<td>Oncology Network</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>C-163</td>
<td>Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer</td>
<td>Oncology Network</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>C-299</td>
<td>Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive Stage Small Cell Lung Cancer</td>
<td>Oncology Network</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>C-233</td>
<td>Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy</td>
<td>Center Pointe</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>C-305</td>
<td>A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovaalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high SCLC who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)</td>
<td>Center Pointe, Cumming, Kennestone</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>Protocol</td>
<td>Title</td>
<td>Study Site</td>
<td>PI Name</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>C-306</td>
<td>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer</td>
<td>Oncology Network</td>
<td>Dr. Crain Garrot</td>
</tr>
<tr>
<td></td>
<td>[<a href="https://www.clinicaltrials.gov/ct2/show/NCT03072238">https://www.clinicaltrials.gov/ct2/show/NCT03072238</a>]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-204</td>
<td>A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation</td>
<td>Oncology Network</td>
<td>Dr. Lijo Simpson</td>
</tr>
<tr>
<td>A071102</td>
<td>[<a href="https://www.clinicaltrials.gov/ct2/show/NCT02152982">https://www.clinicaltrials.gov/ct2/show/NCT02152982</a>]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuro</td>
<td>A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate (TL) + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC in stage III and stage IV (resected) melanoma to prevent recurrence</td>
<td>Oncology Network</td>
<td>Dr. Ronald Steis</td>
</tr>
<tr>
<td>C-188</td>
<td>[<a href="https://www.clinicaltrials.gov/ct2/show/NCT02301611">https://www.clinicaltrials.gov/ct2/show/NCT02301611</a>]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elios</td>
<td>Multi-center phase I/IIa trial of an autologous tumor lysate (TL) + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine in addition to standard of care checkpoint inhibitor of choice in metastatic melanoma patients with stable or slowly progressing disease</td>
<td>Oncology Network</td>
<td>Dr. Aaron Alizadeh</td>
</tr>
<tr>
<td>2014-1932</td>
<td>[<a href="https://www.clinicaltrials.gov/ct2/show/NCT02678741">https://www.clinicaltrials.gov/ct2/show/NCT02678741</a>]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-267</td>
<td>A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-Drug Conjugate, in Patients with Advanced Melanoma</td>
<td>Oncology Network</td>
<td>Dr. Aaron Alizadeh</td>
</tr>
<tr>
<td>Elios vaccine</td>
<td>[<a href="https://www.clinicaltrials.gov/ct2/show/NCT02302339">https://www.clinicaltrials.gov/ct2/show/NCT02302339</a>]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015-2397</td>
<td>Stage III or IV Resected NED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stable/ Slowly Progressive Dz</td>
<td>[<a href="https://www.clinicaltrials.gov/ct2/show/NCT02521870">https://www.clinicaltrials.gov/ct2/show/NCT02521870</a>]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-207</td>
<td>A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-Drug Conjugate, in Patients with Advanced Melanoma</td>
<td>Oncology Network</td>
<td>Dr. Aaron Alizadeh</td>
</tr>
<tr>
<td>CDX011-05</td>
<td>[<a href="https://www.clinicaltrials.gov/ct2/show/NCT02302339">https://www.clinicaltrials.gov/ct2/show/NCT02302339</a>]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td>Stage III or IV Unresected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-281</td>
<td>A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma</td>
<td>Alpharetta &amp; Stemmer</td>
<td>Dr. Aaron Alizadeh</td>
</tr>
<tr>
<td>DV3-MEL-01</td>
<td>[<a href="https://www.clinicaltrials.gov/ct2/show/NCT02521870">https://www.clinicaltrials.gov/ct2/show/NCT02521870</a>]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage III or IV 1st or 2nd Line</td>
<td>[<a href="https://www.clinicaltrials.gov/ct2/show/NCT02224781">https://www.clinicaltrials.gov/ct2/show/NCT02224781</a>]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-293</td>
<td>A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma</td>
<td>Oncology Network</td>
<td>Dr. Ronald Steis</td>
</tr>
<tr>
<td>ECOG EA6134</td>
<td>[<a href="https://www.clinicaltrials.gov/ct2/show/NCT02224781">https://www.clinicaltrials.gov/ct2/show/NCT02224781</a>]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advanced BRAFV600</td>
<td>[<a href="https://www.clinicaltrials.gov/ct2/show/NCT02224781">https://www.clinicaltrials.gov/ct2/show/NCT02224781</a>]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Clinical Trials January 2018

<table>
<thead>
<tr>
<th>Protocol</th>
<th>Title</th>
<th>Study Site</th>
<th>PI Name</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sarcoma</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-275</td>
<td>A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma</td>
<td>Center Pointe</td>
<td>Dr. Gina D’Amato</td>
</tr>
<tr>
<td>ISB-MC-JGDL</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02659020">https://www.clinicaltrials.gov/ct2/show/NCT02659020</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-308</td>
<td>A Randomized Phase 3 Trial of TRC105 and Pazopanib versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS)</td>
<td>Center Pointe</td>
<td>Dr. Gina D’Amato</td>
</tr>
<tr>
<td>105SAR301</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02979899">https://www.clinicaltrials.gov/ct2/show/NCT02979899</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Angiosarcoma</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSH1124</td>
<td>A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients with Previously Treated, Unresectable Myxoid Liposarcoma</td>
<td>Center Pointe</td>
<td>Dr. Gina D’Amato</td>
</tr>
<tr>
<td>A091202</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02249949">https://www.clinicaltrials.gov/ct2/show/NCT02249949</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Liposarcoma</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-297</td>
<td>A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors</td>
<td>Center Pointe</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>BMS C017-003</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02658890">https://www.clinicaltrials.gov/ct2/show/NCT02658890</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal, NSCLC, Melanoma cohorts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSH1097</td>
<td>A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies</td>
<td>Center Pointe</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>INCB52793-101</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02265510">https://www.clinicaltrials.gov/ct2/show/NCT02265510</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No open cohorts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AML, MDS cohorts on hold for DLT eval</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Multiple Dz Sites / Phase I</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-269</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers</td>
<td>Oncology Network</td>
<td>Dr. Rodolfo Bordoni</td>
</tr>
<tr>
<td>INCB24360-202</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02178722">https://www.clinicaltrials.gov/ct2/show/NCT02178722</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECHO-202</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRC (MSI High) &amp; HCC cohorts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-228</td>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
<td>Oncology Network</td>
<td>Dr. Amelia Zelnak</td>
</tr>
<tr>
<td>ECOG EAY131</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02465060">https://www.clinicaltrials.gov/ct2/show/NCT02465060</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCI MATCH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Targeted therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-265</td>
<td>Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)</td>
<td>Oncology Network</td>
<td>Dr. Guilherme Cantuaria</td>
</tr>
<tr>
<td>DCP-001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDDR</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>